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metabolism can be simultaneously determined using rapidly inter-
leaved arterial spin labelled and BOLD imaging, deoxy-myoglobin
proton spectroscopy and phosphorus spectroscopy during exercise
protocols. They provide valuable information on the respective con-
tributions of oxygen supply, extraction and utilization to particular
conditions or diseases.
doi:10.1016/j.nmd.2009.06.005
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Neuromuscular hereditary disorders (NMDs) represent heteroge-
neous phenotypes intensively studied both in terms of accurate
genetic deﬁnition and pathophysiology. Since therapeutic
approaches are now becoming reality in some NMDs, clinical trials
have been designed to track down correction of a decline in muscle
function, requiring large samples and lengthy times. In addition,
clinical outcome measures may not always be sensitive enough to
detect small changes in disease progression/regression and after
short treatment periods. It is therefore imperative to be able to doc-
ument beneﬁts of the treatment at the individual level to justify
demanding, risky, and expensive treatments. Biomarkers can effec-
tively increase our capacity of studying and monitoring NMDs. They
can be deﬁned as diagnostic if able to implement the genotype–phe-
notype correlation, as well as to label the disease course; pathophys-
iological, when they disclose or integrate common pathways,
therapeutic (pharmacogenetic, pharmacodynamic, pharmacokinetic
and safety) when they can be translated into clinical trials. Other dis-
ciplines, such as oncology, routinely use biomarkers as surrogate or
enrichment endpoints of treatments.
Examples of genomic (DNA and RNA) and proteomic biomarkers
as gene-expression-based or genome signatures will be described in
two pathologies (dystrophiniopathies and collagen VI myopathies)
considered as paradigmatic examples for biomarkers discovery in
NMDs. Particular emphasis will be put on less/non-invasive bio-
markers, a crucial point in the selected disorders but more in general
in many NMDs, where invasive sometimes multiple procedures are
often required in order to demonstrate the efﬁcacy of the treatment.
Moving toward biomarkers in more accessible human cells or ﬂuids
will minimize the invasiveness of the follow up allowing us period-
ical measurements. This is a turning point in the research of NMDs
since new therapies are emerging.
doi:10.1016/j.nmd.2009.06.006
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Introduction: Canine X-linked muscular dystrophy (CXMD) is
caused by a point mutation at the splice acceptor site of exon 7 of
the dystrophin gene, resulting in complete absence of dystrophin.
To explore potential therapeutic approaches to DMD, we have estab-
lished a beagle-based CXMD colony in Japan (CXMDJ). The pheno-
type of CXMDJ was similar, but a little milder than that of golden
retriever CXMD. Evaluation of antisense morpholino-mediated exon
skipping using dog models: Systemic delivery of morpholino antisense
oligonucleotides targeting exon 6 and 8 of the canine dystrophin
gene, efﬁciently recovered functional dystrophin expression at the
sarcolemma of dystrophic dogs, and improved performance of af-
fected dogs without serious side effects (Yokota et al., Ann Neurol,
in press). We have also tested antisense morpholinos targeting exon
51 of the mouse dystrophin gene in mdx 52 mice, in which gene tar-
geting had disrupted exon 52 of the mouse dystrophin gene. Sys-
temic delivery of a combination of two morpholinos showed an
excellent restoration of sarcolemmal dystrophin and amelioration
of the phenotypes in the mice. Signiﬁcance of dystrophic dogs: Overall,
the results using dystrophic mice are more stable than those in dys-
trophic dogs, partly because dystrophic dogs show a variation in the
phenotypes even in a colony. Moreover, one must carefully evaluate
the therapeutic effects within a limited number of dystrophic dogs,
which is another disadvantage of dystrophic dogs. In addition, the
gene mutation in CXMD is not common in DMD patients, therefore
we cannot directly apply the morpholino sequences optimized in
dogs to many human DMD patients. Dystrophic dogs, however, have
a severe progressive course and clinical signs similar to DMD,
whereas mdx mice exhibit mild clinical features. Thus, a combina-
tion of mouse and dog dystrophic models would be ideal to evaluate
the therapeutic effects.
doi:10.1016/j.nmd.2009.06.007
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The diagnosis of muscular dystrophies or the assessment of the
functional beneﬁt of gene or cell therapies can be difﬁcult, espe-
cially for poorly accessible muscles, and it often lacks a single-
ﬁber resolution. In the present study, we evaluated whether mus-
cle diseases can be diagnosed from small biopsies using atomic
force microscopy (AFM). AFM was shown to provide a sensitive
and quantitative description of the resistance of normal and dys-
trophic myoﬁbers within live muscle tissues explanted from Duch-
enne mdx mice. The rescue of dystrophin expression by gene
therapy approaches led to the functional recovery of treated dys-
trophic muscle ﬁbers, as probed using AFM and by in situ whole-
muscle strength measurements. Comparison of muscles treated
with viral or non-viral vectors indicated that the efﬁcacy of the
gene transfer approaches could be distinguished with a single
myoﬁber resolution. This indicated full correction of the resistance
to deformation in nearly all of the muscle ﬁbers treated with an
adeno-associated viral vector that mediates exon-skipping on the
dystrophin mRNA.
Having shown that AFM can provide a quantitative assessment of
the expression of muscle proteins and of the muscular function in
animal models, we assessed myoﬁber resistance in the context of
human muscular dystrophies and myopathies. Thus, various forms
of human Becker syndrome can also be detected using AFM in blind
studies of small frozen biopsies from human patients.
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Interestingly, it also allowed the detection of anomalies in a frac-
tion of the muscle ﬁbers from patients showing a muscle weakness
that could not be attributed to a known molecular or genetic defect.
Overall, we conclude that AFM may provide a useful method to com-
plement current diagnosis tools of known and unknown muscular
diseases, in research and in a clinical context.
doi:10.1016/j.nmd.2009.06.008
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Calpain 3 (CAPN3) is a member of the calpain family of cysteine
proteases and is mutated in Limb Girdle Muscular Dystrophy
(LGMD) type 2A. Three prevailing hypotheses exist for CAPN3 path-
ogenesis: (1) deregulated (in)activation of CAPN3 itself, (2) protease
mislocalisation, and (3) deregulation of a limited number of sub-
strates critically important for muscle ﬁber homeostasis. However,
in the absence of knowledge how CAPN3 recognizes its substrates,
large scale identiﬁcation of its targets is impossible and conse-
quently the exact pathomechanism of LGMD2A remains largely elu-
sive. Using a combination of bio-informatics and biochemical
analyses we identiﬁed a primary amino acid sequence motif under-
lying CAPN3 substrate recognition. This motif is common to all 11
reported CAPN3 substrates, and can transform a non-related protein
into a substrate. The motif identiﬁes >300 new CAPN3 targets with
>90% accuracy. Among the new CAPN3 target proteins we identiﬁed
the Protein Inhibitors of Activated Stats (PIAS) family of E3 sumoyl
ligases as substrates for CAPN3 cleavage and observed that CAPN3
can negatively regulate PIAS3 sumoylase activity. Bioinformatic
analysis of our predicted substrates suggest that CAPN3 functions
as an orchestrator of rapid local changes in cyto-architecture.
doi:10.1016/j.nmd.2009.06.009
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Autosomal dominant facioscapulohumeral muscular dystrophy
(FSHD) is the secondmost commonmyopathy in adults. FSHD is clin-
ically characterized by progressiveweakness andwasting of the facial,
shoulder and upper arm muscles, often in an asymmetric fashion.
Genetically, FSHD is associatedwith a contraction of the D4Z4macro-
satellite repeat in the chromosome4qsubtelomere in>95%ofpatients.
In healthy individuals this polymorphic repeat can vary between
11-100 D4Z4 units, each unit being 3.3 kb in size. Patients with FSHD
carry one allelewith a D4Z4 repeat of 1–10 units. However, D4Z4 con-
traction is not sufﬁcient to cause FSHDas it needs to occur on a speciﬁc
genetic background: the subtelomeric 4qA161 haplotype. Contrac-
tions in other 4q haplotypes and in chromosome 10q carrying a highly
homologous repeat are non-pathogenic.
We have performed a detailed DNA methylation study of the
D4Z4 repeat and proximal sequences on chromosomes 4q and 10q.
FSHD patients with a D4Z4 contraction (FSHD1) show contraction-
dependent hypomethylation, which is restricted to D4Z4 and limited
to the disease allele. Importantly, hypomethylation occurs irrespec-
tive of the genetic background of the repeat. Thus, control individu-
als with a D4Z4 contraction on a non-pathogenic 4q haplotype or on
chromosome 10q also present with hypomethylation. In ﬁfteen
FSHD families without D4Z4 contractions (FSHD2), we observed
D4Z4-restricted, contraction-independent hypomethylation on chro-
mosomes 4q and 10q, including at least one copy of the pathogenic
haplotype as seen in FSHD1. This implies that a genetic defect result-
ing in D4Z4 hypomethylation at chromosomes 4q and 10q underlies
FSHD2. In conclusion, our data support the hypothesis that the com-
bination of a chromatin change in D4Z4 on a 4qA161 haplotype uni-
ﬁes FSHD1 and FSHD2.
doi:10.1016/j.nmd.2009.06.010
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Approximately one billion people worldwide are homozygous for
a stop codon polymorphism in the ACTN3 gene (R577X) which re-
sults in complete deﬁciency of the fast muscle protein a-actinin-3.
ACTN3 genotype is associated with human athletic performance with
the 577XX genotype being under-represented in sprint athletes and
over-represented in endurance athletes. Using a knock-out mouse
model of a-actinin-3 deﬁciency, we have previously demonstrated
a shift in the properties of fast muscle ﬁbres in a-actinin-3 deﬁcient
individuals towards slower ﬁbre properties;of note there is increased
activity of multiple enzymes in the aerobic metabolic pathway in the
KO mouse muscle. This provides an explanation for the link between
577XX genotype and athletic performance and muscle function in
humans.
We aimed to determine the molecular mechanism(s) underlying
the metabolic changes seen in muscle in the absence of a-actinin-3.
We show that a speciﬁc subset of structural muscle proteins is up-
regulated in the absence of a-actinin-3, including a-actinin-2, myo-
tilin, desmin and c-ﬁlamin. Although sarcomeric localisation of these
proteins is not grossly affected we see cytoplasmic inclusions of
myotilin in the knock-out mouse muscle suggesting subtle structural
differences in muscles lacking a-actinin-3. Interestingly these inclu-
sions also contain glycogen phosphorylase (GPh). We demonstrate
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